Physician profile
Julia Schroer
NPI 1316677321
$948.17
in general payments reported to CMS, 2019-2025
11 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $124 · 2024: $536 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $305.07 | 2024 | Perclot |
| Veloxis Pharmaceuticals, INC. | $187.35 | 2023-2025 | Envarsus |
| Novo Nordisk INC | $113.16 | 2025 | Saxenda, Wegovy |
| Mimedx Group, INC. | $89.15 | 2024 | |
| Merck Sharp & Dohme LLC | $69.42 | 2023-2024 | Dificid, Recarbrio, Zerbaxa |
| Alexion Pharmaceuticals, INC. | $44.42 | 2023-2024 | Ultomiris |
| Medical Device Business Services, INC. | $36.46 | 2025 | Echelon Flex |
| Abbvie INC. | $34.28 | 2024 | |
| Ethicon US, LLC | $33.49 | 2024 | Echelon Flex, Harmonic, Enseal |
| Conmed Corporation | $19.51 | 2024 | Conmed Specimen Retrieval, Airseal |
| Takeda Pharmaceuticals U.S.A., INC. | $15.86 | 2024 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Schroer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.